Comparative Pharmacology
Head-to-head clinical analysis: DENAVIR versus ZOVIRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENAVIR versus ZOVIRAX.
DENAVIR vs ZOVIRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DENAVIR is a synthetic peptide that inhibits viral replication by preventing the fusion of the viral envelope with the host cell membrane. It specifically targets the HIV-1 envelope glycoprotein gp41, blocking the conformational changes required for membrane fusion.
After intracellular phosphorylation to acyclovir triphosphate, selectively inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination.
5 mg applied topically to affected area once daily for 4 weeks.
Herpes simplex: 200 mg orally 5 times daily for 10 days; or 400 mg orally 3 times daily for 5-10 days. Herpes zoster: 800 mg orally 5 times daily for 7-10 days. IV: 5-10 mg/kg every 8 hours for immunocompromised patients with HSV/VZV.
None Documented
None Documented
Terminal elimination half-life is 2.5–3.5 hours in patients with normal renal function. Prolonged to 20–40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 2.5-3.3 hours in adults with normal renal function; prolonged to 19.5 hours in anuria (creatinine clearance <10 mL/min).
Renal excretion of unchanged drug accounts for approximately 90% of the administered dose via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 76-82% of elimination; fecal excretion is less than 2%.
Category C
Category C
Antiviral
Antiviral